Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of CKD-382, D860, and D027 in Healthy Subjects
NCT05108038Phase 1Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- Oct 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of esomeprazole and sodium bicarbonate in gastroesophageal reflux disease (GERD) (6 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Primary Pharmacokinetic Endpoint and Primary Pharmacodynamic Endpoint at 24 hours. Status: unknown.
02
Drugs
esomeprazolesodium bicarbonate
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05108038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05108038.